Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos, which are delivered through artificial insemination to breed dairy and beef cattle with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers; and agricultural and agri-food consultancy services. Genus plc was incorporated in 1994 and is headquartered in Basingstoke, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-1256-347100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£470.50 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Genus (LON:GNS) Frequently Asked Questions
What is Genus' stock symbol?
Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS."
How often does Genus pay dividends? What is the dividend yield for Genus?
Genus declared a dividend on Thursday, February 28th. Shareholders of record on Thursday, March 7th will be given a dividend of GBX 8.90 per share on Thursday, April 4th. This represents a yield of 0.41%. The ex-dividend date is Thursday, March 7th. The official announcement can be accessed at this link. View Genus' Dividend History.
What price target have analysts set for GNS?
4 analysts have issued 1 year target prices for Genus' stock. Their predictions range from GBX 2,500 to GBX 2,700. On average, they expect Genus' stock price to reach GBX 2,607.50 in the next year. This suggests a possible upside of 10.4% from the stock's current price. View Analyst Price Targets for Genus.
What is the consensus analysts' recommendation for Genus?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genus.
Has Genus been receiving favorable news coverage?
News coverage about GNS stock has been trending somewhat negative on Saturday, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genus earned a news sentiment score of -1.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days.
Who are some of Genus' key competitors?
Some companies that are related to Genus include Cronos Group (CRON), BTG (BTG), MorphoSys (MOR), MorphoSys (MOR), Abcam (ABC), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), Mesoblast (MSB), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Theratechnologies (TH), Biotest (BIO), Polynovo (PNV), Oxford BioMedica (OXB) and Senesco Technologies (ELOX).
What other stocks do shareholders of Genus own?
Who are Genus' key executives?
Genus' management team includes the folowing people:
- Mr. Karim Bitar, CEO & Exec. Director (Age 54)
- Mr. Stephen Wilson, Group Fin. Director & Exec. Director (Age 59)
- Dr. Jonathan Lightner, Chief of R&D and Scientific Officer
- Mr. Dan Hartley, Group Gen. Counsel & Company Sec.
- Ms. Angelle R. Rosata, Group HR Director
How do I buy shares of Genus?
Shares of GNS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Genus' stock price today?
One share of GNS stock can currently be purchased for approximately GBX 2,362.
How big of a company is Genus?
Genus has a market capitalization of £1.52 billion and generates £470.50 million in revenue each year.
What is Genus' official website?
How can I contact Genus?
Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company can be reached via phone at +44-1256-347100.
MarketBeat Community Rating for Genus (LON GNS)
MarketBeat's community ratings are surveys of what our community members think about Genus and other stocks. Vote "Outperform" if you believe GNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
